1.2. Pediatrics

Gabapentin is FDA-approved for use as adjunctive therapy for partial seizures with or without generalization in pediatric epileptic patients 12 years of age and older, as well as adjunctive therapy for partial seizures in pediatric patients 3 years to 12 years of age^1-5. Gabapentin extended-release formulations are not approved for use in pediatric patients as safety and efficacy in this patient population have not been established^{1-4, 6, 7}. Maximum recommended pediatric gabapentin dosages are summarized in Table 2⁵. The maximum time interval between gabapentin doses should not exceed 12 hours. Patient profiles containing gabapentin doses greater than maximum recommendations will be reviewed.